Results 111 to 120 of about 57,115 (246)
Voltammetric Characterisation of Anticancer Drug Irinotecan
, 2017 Electrochemical reduction of irinotecan was investigated on a static mercury drop electrode using square-wave voltammetry. The mechanism of irinotecan electroreduction is a complex, pH-dependent, quasireversible process and includes the transfer of two ...
Jovanović-Novak, Ivana +9 more
core +1 more source
Histopathology, EarlyView.TAC/SARIFA, defined by direct tumour–adipocyte contact at the invasion front, represents a reproducible, biologically meaningful H&E biomarker with consistent adverse prognostic associations in CRC. Aims Direct tumour‐adipocyte interaction at the invasion front, termed Stroma AReactive Invasion Front Areas (SARIFA), has recently emerged as a novel H&E ...
Nic G Reitsam +3 more
wiley +1 more source
A Roadmap to Individualized Irinotecan Dosing [PDF]
, 2006 Ever since its introduction to the drug-market in the late eighties, early nineties of the last century, irinotecan is fighting its image. Particularly, the unpredictable occurrence and severity of delayed-type diarrhea, its main dose-limiting ...
de Jong, FA (Floris) +1 more
core +1 more source
, 2021 Treatment with pharmacological drugs for colorectal cancer (CRC) remains unsatisfactory. A major cause of failure in pharmacotherapy is the resistance of colon cancer cells to the drugs, creating an urgent issue.
Habano, Wataru +3 more
core
DEN Open, Volume 7, Issue 1, April 2027.ABSTRACT Concurrent malignant biliary obstruction (MBO) and type I duodenal stenosis represent a technically demanding scenario, as luminal narrowing frequently precludes passage of a standard side‐viewing duodenoscope and limits conventional transpapillary drainage.
Kengo Matsumoto +8 more
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 8, Page 2075-2083, 15 October 2026.Bevacizumab added to systemic chemotherapy remains a cornerstone of metastatic colorectal cancer treatment, but its effectiveness is variable. Tumors can bypass the VEGF blockade by activating other pro‐angiogenic pathways, hampering the identification of predictive biomarkers.
Büsra Akay Hacan +9 more
wiley +1 more source
Response of small intestinal epithelial cells to irinotecan.
, 2013 (A) Significant decrease in the number of BrdU postive cells in the small intestinal crypts of irinotecan-treated mice. WT mice were injected with PBS (cont) or irinotecan (CPT) for 6 consecutive days and sacrificed on day 7. One hour prior to sacrifice,
Helen Piwnica-Worms (251639) +5 more
core +1 more source
, 2014 642 Background: Panitumumab and cetuximab are known to be effective in KRAS wild-type metastatic colorectal cancer (mCRC). However, it is not clear whether panitumumab and irinotecan confers benefit that are comparable to those of cetuximab and ...
Yoshitaka Honma +7 more
core +1 more source
International Journal of Cancer, Volume 159, Issue 7, Page 1817-1828, 1 October 2026.Antiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...
Jurek Hille +17 more
wiley +1 more source
Generation of the Camptothecin Scaffold by a Flavin‐Catalyzed Photooxidative Skeletal Reorganization
Angewandte Chemie, Volume 138, Issue 36, 1 September 2026.The biosynthetic pathway of the anticancer drug precursor camptothecin involves an enigmatic skeletal reorganization from a 6/5/6 tetrahydro‐β‐carboline to a 6/6/5 pyrroloquinoline ring system. Here, we show that this transformation can be achieved by photooxidation with flavin cofactors, such as flavin mononucleotide (FMN) as catalysts.
Shenyu Liu +6 more
wiley +2 more sources